Therapeutic efficacy of 188Re-human serum albumin microspherein GP7TB hepatoma model via intra-arterial route

3^rd World Congress on Cancer Science & Therapy

October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

Liang-Cheng Chen, Wan-Chi Lee, Chung-Li Ho, Hsiao-Chiang Ni, Su-Jung Chen, Chih-Hsien Chang and Te-Wei Lee

ScientificTracks: J Cancer Sci Ther

Abstract :

The aim of this study was to investigate the therapeutic efficacy of intra-arterially administrated 188 Re-human serum albumin microsphere ( 188 Re-HSAM) in the GP7TB hepatoma model. Male F344 rats were done with intrahepatic inoculation with GP7TB 1 mm 3 cubes. These studies were performed on rat at 26 d after tumor inoculation. The efficacy of 188 Re-HSAM was performed by a single-dose treatment in GP7TB hepatoma rat via intra-arterial route. Rats were checked for survival every day until death. The body weight was measured once a week. In efficacy study, the median survival time for the rat (n=3), which received normal saline was 80 d. The median survival times for the mice treated with 10 mCi (n=3), 4.8 mCi (n=3) and 2.9 mCi (n=3) of 188 Re-HSAM were 130 d (P=0.003), 90.25 d (P=0.035) and 83.5 d (P=0.617), respectively. The increase in life span of 10 mCi, 4.8 mCi and 2.9mCi of 188 Re-HSAM were 62.5%, 12.8% and 4.4% respectively. The therapeutic studies of 188 Re-HSAM demonstrated better survival time and therapeutic efficacy for rat with increased dose in the GP7TB hepatoma model. These results suggested that intra-arterial administration of 188 Re-HSAM could provide a benefit and promising strategy for delivery of radiotherapeutics in oncology applications.

Biography :

Liang-Cheng Chen is the Assistant Researcher of Isotope Application Division in Institute of Nuclear Energy Research. His major work is to investigate the preclinical animal study for drug efficacy, pharmacokinetics, dosimetry, molecular imaging and toxicology.